Physicians' Academy for Cardiovascular Education

Analogous to LDL-c, the lower the better also seems true for inflammation

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

Imaging components of plaque not more informative than burden of plaque

Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

Aug. 28, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

Aug. 27, 2017

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Inflammation, the immune system and atherosclerosis

July 7, 2015 - Amsterdam IAS

ESC/EAS statin eligibility criteria in primary prevention should include very high TG levels

Nov. 29, 2017 - Madsen CM et al., - Eur Heart J 2017

In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.

WOSCOPS analysis supports LDL-C lowering for primary prevention at high LDL-c without risk assessment

Nov. 20, 2017 - Vallejo-Vaz AJ, et al. - Circulation 2017

Men with LDL-C levels ≥190 mg/dL without atherosclerotic CVD, have a 2-fold higher risk of major CV events than would be predicted with a risk calculator.

Analogous to LDL-c, the lower the better also seems true for inflammation

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA
A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but respons to treatment did.

AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but response to treatment did.

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Response to anti-inflammatory treatment explains CV benefit in CANTOS trial

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Paul Ridker (Brigham and Woman’s Hospital, Boston, MA, VS).

Nov. 13, 2017 - news

AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP < 2 mg/L benefitted from a reduction in MACE and mortality, irrespective of the dose of canakinumab.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

CAC measurements predict HFpEF risk in women

Nov. 6, 2017 - Sharma K, et al. - Am J Cardiol 2017

In asymptomatic individuals without clinical CVD, measurement of CAC was helpful for the risk stratification of HFpEF in women, not in men.

Targeting IL-1beta to lower inflammation and thereby CV events proved sensible

Oct. 31, 2017 - Peter Libby - J Am Coll Cardiol. 2017

This review summarizes the rationale to specifically target IL-1beta to lower residual inflammatory risk, now shown to be effective in the CANTOS trial. Other potential targets are also discussed.

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Inflammation Expert Opinions Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Inflammation expert opinions

Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Inflammation Expert Opinions Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Anti-inflammatory agent favorably modifies vulnerable coronary plaque

Oct. 24, 2017 - Vaidya K et al. - JACC Cardiovasc Imaging. 2017

A year of treatment with low-dose colchicine significantly lowered low attenuation plaque volume and hsCRP levels, as compared with optimal medical treatment in patients with recent ACS.

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Inflammation expert opinions

Aug. 27, 2017
According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Inflammation Expert Opinions According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.